Recent studies show psychedelics like ibogaine may treat traumatic brain injury, chronic pain, and other conditions that traditional medicine struggles with. However, these substances remain illegal or heavily restricted in most countries, limiting research and patient access. Governments worldwide are deciding whether to invest in this emerging field.